Central Alabama Research | Birmingham, AL

Research site

(Unclaimed)

Location

10 Old Montgomery Highway, Suite 100, Birmingham, Alabama, United States of America

Site insights

Top conditions

Top treatments

Metformin

Triglyceride

Tanezumab

K-877

Obicetrapib

Bococizumab

casirivimab+imdevimab

Semaglutide

Panitumumab

Polypill

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 36 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling

Primary Prevention of Atherosclerotic Cardiovascular Disease

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Drug: Placebo in 1.5ml

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (ECHELON-3)

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will stu...

Active, not recruiting

Diffuse Large B-cell Lymphoma

Drug: Rituximab

Drug: Lenalidomide

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Obicetrapib

Drug: Placebo

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with I...

Enrolling

Non-small Cell Lung Cancer

Drug: Pembrolizumab (MK-3475) 200 mg

Device: NovoTTF-200T

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, c...

Active, not recruiting

Nonsmall Cell Lung Cancer

NSCLC

Drug: Immune checkpoint inhibitors or docetaxel

Device: NovoTTF-200T

Enlicitide Decanoate (MK-0616) (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling

Arteriosclerosis

Hypercholesterolaemia

Drug: Enlicitide decanoate

Drug: Placebo

Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine (MODEL)

The purpose of the study is to confirm the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and related d...

Enrolling

Lumbar Degenerative Disc Disease

Drug: SB-01 For Injection

Drug: Sham Needle

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection (SCORPIO-PEP)

The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-Co...

Enrolling

SARS-CoV-2 Infection

Drug: Placebo

Drug: S-217622

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholester...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Dyslipidemias

Drug: Placebo

Drug: Obicetrapib

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak300)

The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated...

Active, not recruiting

Colorectal Cancer (CRC)

Drug: Regorafenib

Drug: Panitumumab